About

Gregory G. Ginsberg, MD, is a Professor of Medicine specializing in Gastroenterology at the Hospital of the University of Pennsylvania. He serves as the Executive Director of Endoscopic Services within the University of Pennsylvania Health Systems. His educational background includes a B.S. in Biology from Lafayette College, an M.S. from Villanova University, and an M.D. from Jefferson Medical College. Dr. Ginsberg's professional focus encompasses advanced endoscopy and gastrointestinal research, contributing to the field through numerous publications on topics such as endoscopy outcomes, microbiota and metabolite-based prediction tools for colonic polyposis, serum bile acid profiles related to Barrett's Esophagus and esophageal adenocarcinoma, and artificial intelligence applications in Barrett's neoplasia detection. His work is characterized by a commitment to improving endoscopic procedures and gastrointestinal disease management through research and clinical innovation.

Research topics

• Internal medicine
• Medicine
• Gastroenterology
• Surgery
• Computer Science
• Oncology
• Biology
• Pathology
• Radiology
• Medical physics
• Cancer research

Selected publications

• Extended surveillance after piecemeal endoscopic mucosal resection: a safe approach to initial surveillance in low-risk patients

  Gastrointestinal Endoscopy · 2025-10-20 · 2 citations

  articleOpen accessSenior author

  BACKGROUND AND AIMS: Piecemeal endoscopic mucosal resection (EMR) is the standard of care for large, nonpedunculated colon polyps but is associated with recurrence rates of 9% to 31%. Current guidelines recommend 6-month surveillance for all patients, although this may not be necessary for lower-risk cases. METHODS: We retrospectively reviewed patients who underwent piecemeal EMR of ≥20-mm colon polyps between 2018 and 2021. Patients were stratified into 6- or 12-month surveillance groups based on polyp features. Recurrence rates and associated factors were compared. RESULTS: Among 193 patients, recurrence was higher in the 6-month (31.5%) than in the 12-month group (14.3%, P < .05). Among patients with recurrence, the 6-month follow-up group had more tubulovillous adenomas (P < .05) on index colonoscopy. Tubulovillous histology in the initial polyp was the only factor associated with recurrence. CONCLUSIONS: A risk-stratified approach may safely extend surveillance to 12 months for lower-risk patients after piecemeal EMR, reducing unnecessary procedures without compromising care.

  PublisherDOI

• Increased reflux secondary bile acids are associated with changes to the microbiome and transcriptome in Barrett’s esophagus

  Gut Microbes · 2025-08-22 · 8 citations

  articleOpen access

  showed the most associations with gene expression, including the oxidative phosphorylation pathway. We identified two distinct BE gene expression clusters independent of histology, bile acid, or microbiome composition. These findings suggest bile acids shape the BE microbiome and associate with gene expression changes potentially relevant to EAC development.

  PublisherOA PDFDOI

• CLINICAL AND TECHNICAL FACTORS ASSOCIATED WITH PROTON PUMP INHIBITOR USE POST PER- ORAL ENDOSCOPIC MYOTOMY (POEM)

  Gastrointestinal Endoscopy · 2025-05-01

  articleSenior author
  PublisherDOI

• Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities

  Gastro Hep Advances · 2025-10-30

  articleOpen access

  Endohepatology provides a unison of 2 rapidly developing fields of hepatology and advanced endoscopy. Conventionally, endoscopy in liver disease was restricted primarily to the management of varices. However, multiple new domains have emerged in advanced endoscopy, driven mainly by endoscopic ultrasound (EUS), and as such find several applications in clinical hepatology. Robust data have emerged regarding EUS liver biopsy and the management of gastric varices, and are becoming the first line of care at experienced centers. EUS-guided portal pressure gradient and direct measurements appear to be an exciting frontier for portal pressure assessment. EUS shear wave elastography holds promise but needs standardization and comparison to well-established noninvasive surrogates. Endobariatrics opens up new avenues in optimizing comprehensive obesity management. Interesting crossroads emerge in liver transplantation, where endohepatology may provide a unique single setting investigation and therapeutic solution. Several other potential uses are emerging but need to be replicated across settings. While the advancements usher in excitement, several gaps in knowledge and pragmatic concerns remain with the application of endohepatology, which need to be balanced against patient safety and in optimizing outcomes.

  PublisherDOI

• Gastric epithelium from <i>BRCA1</i> and <i>BRCA2</i> carriers harbors increased double-stranded DNA damage and augmented growth

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-10-03

  preprintOpen access

  Abstract An accumulating body of evidence suggests carriers of a pathogenic germline variant (PGV) in BRCA1 or BRCA2 have increased gastric cancer (GC) risk. BRCA1 and BRCA2 are tumor suppressor genes involved in promoting homologous recombination to repair double-stranded DNA breaks. The aim of this investigation was to identify differences within the gastric epithelium and in patient-derived gastric organoids (PDGOs) between BRCA1 and BRCA2 carriers and non-carriers to determine if evidence of early gastric carcinogenesis exists amongst these carriers. First, using gastric epithelial biopsies, BRCA2 carriers were found to harbor higher expression of the proliferative marker Ki-67 within the antral gastric epithelium and strikingly, biopsies from both BRCA1 and BRCA2 carriers displayed a marked increase in double-stranded DNA damage. These results were further explored using PDGOs, where a growth advantage was observed for both BRCA1 and BRCA2 PDGOs compared to non-carrier PDGOs. Furthermore, both BRCA1 and BRCA2 PDGOs displayed a more pronounced enhancement of Ki-67 expression as well as increased double stranded DNA damage compared to non-carrier PDGOs. Importantly, none of the PDGOs showed signs of BRCA1 or BRCA2 loss of heterozygosity, potentially indicating a haploinsufficient phenotype. Taken together, these novel findings suggest that haploinsufficiency in BRCA1 and BRCA2 carriers may lead to DNA damage in the gastric epithelium, which may serve as an early event contributing to GC development.

  PublisherOA PDFDOI

• Microbiota and metabolite-based prediction tool for colonic polyposis with and without a known genetic driver

  Gut Microbes · 2025-03-11 · 6 citations

  articleOpen access

  H NMR, revealing an increase in alanine in SPS subjects relative to non-polyposis subjects, and Partial Least Squares Discriminant Analysis (PLS-DA) analysis indicated that the proportion of leucine to tyrosine in fecal samples may be predictive of SPS. Use of these microbial and metabolomic signatures may allow for better diagnostric and risk-stratification tools for colonic polyposis patients and their families as well as promote development of microbiome-targeted approaches for polyp prevention.

  PublisherOA PDFDOI

• Endoscopy and anesthesia outcomes associated with glucagon-like peptide-1 receptor agonist use in patients undergoing outpatient upper endoscopy

  Gastrointestinal Endoscopy · 2025-01-15 · 10 citations

  articleOpen access
  PublisherOA PDFDOI

• SINGLE CENTER RETROSPECTIVE STUDY COMPARING Z-POEM AND FEIT-Z IN PATIENTS WITH ZENKER’S DIVERTICULUM

  Gastrointestinal Endoscopy · 2024-06-01

  article
  PublisherDOI

• Mo1241 GASTRIC EPITHELIUM AND PATIENT-DERIVED GASTRIC ORGANOIDS FROM BRCA1/2 CARRIERS HARBOR INCREASED PROLIFERATION AND DNA DAMAGE

  Gastroenterology · 2024-05-01

  article
  PublisherDOI

• Prevalence of <i>H. pylori</i> and Gastric Intestinal Metaplasia in <i>BRCA1</i> and <i>BRCA2</i> Carriers

  Cancer Prevention Research · 2024-04-19

  articleOpen access

  BRCA1 and BRCA2 carriers may be at increased risk for gastric cancer; however, the mechanisms of gastric carcinogenesis remain poorly understood. We sought to determine the prevalence of gastric cancer risk factors Helicobacter pylori (H. pylori) infection and gastric intestinal metaplasia (GIM) among BRCA1/2 carriers to gain insight into the pathogenesis of gastric cancer in this population. A total of 100 unselected BRCA1/2 carriers who underwent endoscopic ultrasound from March 2022 to March 2023 underwent concomitant upper endoscopy with nontargeted gastric antrum and body biopsies. The study population (70% women; mean age 60.1 years) included 66% BRCA2 carriers. H. pylori was detected in one (1%) individual, 7 (7%) had GIM, 2 (2%) had autoimmune atrophic gastritis, and no gastric cancers were diagnosed. Among BRCA1/2 carriers, H. pylori prevalence was low and GIM prevalence was similar to that in the general population; however, identification of H. pylori or GIM may help inform future gastric cancer risk management strategies in BRCA1/2 carriers. Prevention Relevance: Evaluating the burden of H. pylori infection and GIM among BRCA1/2 carriers is warranted to better understand the mechanisms of gastric carcinogenesis and to help inform risk management strategies for gastric cancer among this at-risk population.

  PublisherOA PDFDOI

Frequent coauthors

• Michael L. Kochman

  197 shared

• Drew Schembre

  John Muir Health

  182 shared

• Nuzhat A. Ahmad

  117 shared

• Herbert C. Wolfsen

  116 shared

• Marcia I. Canto

  Johns Hopkins Hospital

  113 shared

• Alan Barkun

  109 shared

• Frank G. Gress

  106 shared

• V. Raman Muthusamy

  102 shared